Bulevirtide: Physiology and What Research Reports
Bulevirtide is a synthetic 47-amino-acid myristoylated lipopeptide copied from the preS1 region of the hepatitis B surface protein. It binds NTCP, the liver bile-acid transporter that hepatitis B and D viruses use to enter hepatocytes, and blocks viral entry. Published phase 3 trials reported reductions in hepatitis D virus RNA with alanine aminotransferase normalisation, while the most commonly described laboratory finding was a dose-related rise in serum bile acids. This page summarises that literature only.
What bulevirtide is
Bulevirtide is not a naturally occurring human hormone or a research-grade "wellness" peptide. It is a synthetic lipopeptide drug: a 47-amino-acid sequence copied from the preS1 domain of the hepatitis B virus (HBV) large surface protein, chemically modified with a myristic acid group at its N-terminus so it anchors into cell membranes. The first-approval review described bulevirtide as a first-in-class entry inhibitor authorised in the European Union for chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease, administered as 2 mg once daily by subcutaneous injection (PMID 32926353).
Readers meeting the term in peptide contexts usually encounter it as an example of receptor-blocking peptide design: a short, precisely engineered sequence that occupies a human transporter rather than activating a hormone receptor.
Where it acts: NTCP and bile-acid physiology
The target is the sodium taurocholate co-transporting polypeptide (NTCP, gene SLC10A1), a transporter expressed on the basolateral (sinusoidal) membrane of hepatocytes. Physiologically, NTCP reclaims conjugated bile salts from portal blood back into liver cells, a central step in enterohepatic bile-acid recirculation. HBV — and HDV, which borrows the HBV envelope — uses the same protein as its entry receptor, attaching through the preS1 sequence that bulevirtide imitates.
That dual role explains both the intended pharmacology and the most characteristic laboratory finding: a peptide that plugs NTCP interrupts viral docking and, at the same time, interrupts hepatic bile-salt uptake. Reviews of bulevirtide-based strategies have framed this on-target bile-acid effect as an expected consequence of the mechanism rather than an off-target toxicity (PMID 36740364).
Structural evidence for the interaction
Structural work has visualised the interaction directly. Researchers reported a structure of bulevirtide bound to the hepatitis B and D virus receptor protein NTCP, showing how the myristoylated peptide engages the transporter and occludes the bile-acid translocation pathway (PMID 38509088). Discovery and development narratives have traced the molecule from preS1 peptide biology to a clinical entry inhibitor (PMID 36712949).
What it does in the body, at tissue level
Because entry inhibition does not clear virus already inside cells, a key physiological question has been whether blocking entry actually shrinks the pool of infected hepatocytes. One study examined human liver biopsies and reported that blocking viral entry with bulevirtide reduced the number of HDV-infected hepatocytes (PMID 38340811). That observation supports the model in which infected cells turn over while re-infection of neighbouring cells is prevented.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHow bulevirtide is measured and studied
Studies of bulevirtide have not relied on peptide blood levels as the main readout. Instead, the literature has used:
- Quantitative HDV RNA in serum, reported as undetectability or as log10 decline from baseline.
- Alanine aminotransferase (ALT) as a biochemical marker of hepatocyte injury; trials have combined virologic and ALT criteria into a single "combined response" endpoint (PMID 37345876).
- Serum bile acids, monitored because NTCP inhibition predictably alters bile-salt handling (PMID 37345876).
- Liver histology and immunohistochemistry, used to count infected hepatocytes in biopsy tissue (PMID 38340811).
What the controlled trials reported
In a phase 3 randomised trial, researchers compared bulevirtide 2 mg daily and 10 mg daily with no antiviral treatment and reported a combined virologic and biochemical response at week 48 in 45% of the 2-mg group, 48% of the 10-mg group and 2% of the untreated comparison group (PMID 37345876). Longer follow-up from the same phase 3 programme reported that efficacy outcomes with bulevirtide monotherapy were maintained or improved through week 96, with a safety profile consistent with the earlier analysis (PMID 38734383).
A separate randomised trial examined bulevirtide combined with pegylated interferon alfa-2a and reported that the combination achieved higher rates of undetectable HDV RNA 24 weeks after the end of therapy than bulevirtide monotherapy or pegylated interferon alone (PMID 38842520).
| Study type | What researchers reported | Citation |
|---|---|---|
| Phase 3 monotherapy, week 48 | Combined response 45% (2 mg), 48% (10 mg), 2% (no treatment) | PMID 37345876 |
| Phase 3 monotherapy, week 96 | Efficacy maintained or improved; safety consistent over time | PMID 38734383 |
| Combination with pegylated interferon | Higher post-treatment undetectable HDV RNA than monotherapy | PMID 38842520 |
| Human liver biopsies | Fewer HDV-infected hepatocytes after entry blockade | PMID 38340811 |
| Receptor structure | Bulevirtide bound to NTCP, occluding the transport path | PMID 38509088 |
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appBulevirtide Tolerability: What Studies Report
In the phase 3 monotherapy trial, researchers reported headache, injection-site reactions, eosinophilia and dose-dependent increases in serum bile acids among treated participants, and described the bile-acid elevations as not associated with symptoms such as pruritus (PMID 37345876). The week-96 analysis of that programme reported that bulevirtide monotherapy remained well tolerated with continued treatment (PMID 38734383). Narrative reviews have noted that when bulevirtide is used together with pegylated interferon, the tolerability picture is dominated by the interferon component, and they have summarised monitoring considerations discussed in the trials (PMID 41287135, PMID 36428959).
This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medicine, a laboratory result or a symptom. Nothing here describes a protocol, and the doses named above are reported only as the quantities the cited studies administered.
Why the term matters in peptide literature
Bulevirtide is frequently cited as a proof-of-concept case in peptide pharmacology for several reasons:
- Sequence borrowed from a pathogen. The active sequence is a viral motif, not a human ligand — an example of using a pathogen's own binding domain as a competitive blocker.
- Lipidation as a design tool. Myristoylation converts a short hydrophilic peptide into a membrane-anchoring molecule with liver-directed distribution, a strategy also discussed in broader peptide-engineering reviews of entry inhibitors (PMID 37853604).
- On-target physiology as a biomarker. Because NTCP is a bile-acid transporter, the rise in serum bile acids reported in trials doubles as evidence of target engagement (PMID 37345876).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeLimits of the current evidence
Reviews have emphasised that entry inhibition suppresses HDV rather than eliminating hepatitis B surface antigen, that optimal treatment duration remains an open research question, and that finite-duration and combination strategies are still being defined (PMID 36740364, PMID 41287135). Other reviews have catalogued alternative HDV approaches beyond entry inhibition, including nucleic-acid and prenylation-targeting agents, reflecting how quickly this field is moving (PMID 36529713). Bulevirtide is a prescription medicine studied in supervised hepatology settings; it is not a general-purpose research peptide, and the literature summarised here describes clinical trial populations with chronic HDV infection.
References
- A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D (The New England Journal of Medicine, 2023)
- Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D (The New England Journal of Medicine, 2024)
- Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial (Journal of Hepatology, 2024)
- Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies (Journal of Hepatology, 2024)
- Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP (Nature Communications, 2024)
- Bulevirtide: First Approval (Drugs, 2020)
- Bulevirtide-based treatment strategies for chronic hepatitis delta: A review (Journal of Viral Hepatitis, 2023)
- Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update (Journal of Viral Hepatitis, 2025)
- Bulevirtide and emerging drugs for the treatment of hepatitis D (Expert Opinion on Biological Therapy, 2023)
- Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy (Drug Design, Development and Therapy, 2023)
- Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update (Cells, 2022)
- Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus (Journal of Viral Hepatitis, 2023)
Frequently asked questions
What is bulevirtide in simple terms?▾
It is a synthetic lipopeptide built from the preS1 region of the hepatitis B surface protein and modified with a fatty-acid tail. The first-approval review described it as a first-in-class entry inhibitor authorised in the European Union for chronic hepatitis delta in adults with compensated liver disease, given as 2 mg once daily subcutaneously (PMID 32926353).
What receptor does bulevirtide bind?▾
It binds NTCP, the sodium taurocholate co-transporting polypeptide on the sinusoidal surface of hepatocytes, which normally reclaims bile salts from portal blood and is also the entry receptor for hepatitis B and D viruses. Researchers reported a structure of bulevirtide bound to NTCP showing how the peptide occludes the transport pathway (PMID 38509088).
What did the phase 3 monotherapy trial report?▾
The study compared bulevirtide 2 mg daily and 10 mg daily with no antiviral treatment and reported a combined virologic and biochemical response at week 48 in 45%, 48% and 2% of those groups respectively (PMID 37345876). A later analysis reported that outcomes were maintained or improved through week 96 (PMID 38734383).
What tolerability findings appear in the trials?▾
In the phase 3 trial, researchers reported headache, injection-site reactions, eosinophilia and dose-dependent increases in serum bile acids, with the bile-acid rise described as unaccompanied by symptoms such as itching (PMID 37345876). The week-96 report described continued tolerability with ongoing treatment (PMID 38734383). This is educational information, not medical advice.
Why do serum bile acids change with an antiviral peptide?▾
Because the target is a bile-acid transporter. NTCP normally pulls conjugated bile salts back into liver cells, so occupying it with a peptide slows that uptake. Reviews of bulevirtide strategies have framed the resulting bile-acid elevation as an expected on-target consequence of the mechanism rather than an unrelated toxicity (PMID 36740364).
Has combining bulevirtide with interferon been studied?▾
Yes. A randomised trial reported that bulevirtide combined with pegylated interferon alfa-2a achieved higher rates of undetectable HDV RNA 24 weeks after the end of therapy than bulevirtide monotherapy or pegylated interferon alone (PMID 38842520). Reviews have noted that combination and finite-duration strategies remain active research questions (PMID 41287135).
Does entry inhibition clear virus from already infected cells?▾
Not directly, but a biopsy study reported that blocking viral entry with bulevirtide reduced the number of HDV-infected hepatocytes in human liver tissue, consistent with infected cells turning over while re-infection is prevented (PMID 38340811). Reviews stress that hepatitis B surface antigen loss is generally not achieved by entry inhibition alone (PMID 36740364).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.